Bayer's $7B Roundup Case Returns to Missouri Court

A federal judge on Wednesday returned Bayer’s (BAYN.DE) $7.25 billion Roundup class-action settlement to Missouri state court, rejecting objectors’ bid to derail the deal in a ruling that preserves – but does not guarantee – the company’s best near-term path to closing out tens of thousands of cancer claims.

With roughly 61,000 to 65,000 Roundup lawsuits still pending and Bayer having already spent more than $11 billion resolving prior claims, the forum ruling is a material catalyst: keeping the settlement on track would cap an open-ended liability that has eroded the company’s market capitalisation to roughly $25 billion – less than half the $63 billion it paid for Monsanto in 2018.

Key Takeaways

Federal judge remands $7.25 billion settlement to Missouri state court.
Final approval hearing remains scheduled for July 9, 2026.
Over 100 class members have filed objections; opt-out deadline was June 4.

Deal Context & Market Pressure

The proposed settlement, filed February 17 in St. Louis Circuit Court and granted preliminary approval by a Missouri judge in March, would resolve both current and future non-Hodgkin lymphoma (NHL) claims over a 21-year payment period ¹. Bayer’s unresolved litigation exposure continues to weigh on the stock, which has trended well below European pharmaceutical peers such as Novartis and Roche over the past three years.

The June 1 transfer of the case to the federal Roundup MDL in California before Judge Vince Chhabria had briefly complicated the settlement timeline. Chhabria has publicly called the deal “filthy” and “legally problematic,” though he has declined to block it, saying any structural defects are for Missouri appellate courts to address ².

Why Objectors Tried to Pull the Case Federal

The removal attempt was engineered by attorney Ashley Keller, who represents 13 plaintiffs alleging they developed NHL after Roundup exposure and who argued before the U.S. Supreme Court against Monsanto in April ². Keller’s novel legal theory cast his clients as effective defendants – the only parties opposing the settlement – which he said entitled them to remove the case to federal court.

Critics of the deal argue it allocates $675 million in attorney fees while delivering an average payout of just $40,000 for residential users diagnosed with aggressive NHL before age 60. “Monsanto and class counsel walked into court hand in hand to ram through a deal that gifts $675 million to class lawyers while leaving present and future cancer victims with a pittance,” Keller said ².

Bayer’s Defence of the Deal

Bayer has consistently defended the settlement as the most viable route to compensation for claimants, citing clogged courts and the risk that individual plaintiffs could wait years for trial. “We remain confident that the long-term and well-financed proposed class settlement plan, which is supported by plaintiff law firms representing thousands of potential class members, is fair to all claimants, and warrants approval by the court,” the company said ².

Chris Seeger, one of the settlement architects, dismissed the removal effort as “a baseless delay tactic that should be promptly denied,” arguing the deal offers “guaranteed compensation for cancer victims who have waited more than a decade for justice” ².

Supreme Court Wildcard

Layered over the settlement fight is a pending Supreme Court ruling in Monsanto v. Durnell, expected before the end of June, on whether federal pesticide law preempts state failure-to-warn claims ². A ruling in Monsanto’s favour could dramatically reduce the value of opt-out plaintiffs’ individual suits – a dynamic Bayer and settlement proponents have used to discourage departures from the class.

More than 100 class members and a dozen health-care plans had filed objections ahead of the July 9 final-approval hearing, citing inadequate notice, burdensome opt-out procedures requiring compliance with 11 separate requirements, and concerns about lien and subrogation rights for health insurers ¹.

Conclusion

Wednesday’s remand order clears one procedural hurdle, but the July 9 hearing before Judge Timothy Boyer in St. Louis remains the decisive event for Bayer’s liability calculus. The combination of objector volume, Supreme Court timing, and an opt-out deadline that has already passed means deal-focused investors face at least several more weeks of uncertainty before the settlement’s fate is known.

Not investment advice. For informational purposes only.